Retinal Detachment

What Is Retinal Detachment?

Retinal detachment, known in medical Latin as ablatio retinae, meaning removal of the retina, is the separation of the retina from the underlying layer of cells that nourish and support it. The retina is the thin, light-sensing inner lining of the eye. It sits against a supportive layer of pigmented cells called the retinal pigment epithelium (RPE), which supplies oxygen and nutrients through direct contact. When the retina separates from the RPE, it loses this vital supply, and visual cells begin to die. Without prompt treatment, retinal detachment can cause permanent, irreversible vision loss.

Retinal detachment is classified as a vitreoretinal emergency. It falls within the category of vitreoretinal diseases—conditions affecting the retina and the vitreous (the clear gel that fills the interior of the eye). Retinal detachment is an umbrella term encompassing three distinct types that differ in how the separation occurs, who it affects, and how it is treated. The overall incidence in the United States is approximately 17.9 per 100,000 persons per year, with rhegmatogenous retinal detachment—the most common type—occurring in roughly 1 in 10,000 people annually. A large U.S. claims-based study identified more than 61,000 incident retinal detachment cases over eight years across 133 million insured persons.

The most important prognostic factor in retinal detachment is whether the macula—the central region of the retina responsible for sharp, detailed vision—has detached. A macula-on detachment, in which the fovea (the very center of the macula) is still attached, carries an excellent prognosis: approximately 90% of patients achieve 20/40 vision or better after successful repair. A macula-off detachment, in which the fovea has separated, carries a substantially worse prognosis: only about 50% of patients recover functional central vision even with successful surgery, and outcomes worsen the longer the macula remains detached. This distinction is why retinal detachment—particularly macula-on detachment—must be treated as a same-day emergency.

Types of Retinal Detachment

Clinicians classify retinal detachment into three major types based on the underlying mechanism that causes the retina to separate from its support layer. Each type has a different cause, appears differently on examination, affects different populations, and is treated differently.

Rhegmatogenous retinal detachment (RRD): The most common type, accounting for 60–80% of all retinal detachments. The word rhegmatogenous comes from the Greek rhegma, meaning break or tear. In RRD, a full-thickness break—a tear or hole—develops in the retina. Liquefied vitreous fluid seeps through this opening into the space between the retina and the RPE, progressively separating the retina from its support. RRD is most often associated with posterior vitreous detachment (the age-related separation of the vitreous gel from the retinal surface), myopia (nearsightedness), prior cataract surgery, and trauma.
Tractional retinal detachment (TRD): caused by fibrovascular membranes that grow on the retinal surface and physically pull the retina away from the RPE without any retinal break. The retina has a characteristic concave, tent-like shape. TRD is most commonly seen in people with proliferative diabetic retinopathy—the most serious eye complication of diabetes—in which retinal ischemia drives the growth of abnormal new blood vessels and scar tissue. Other causes include retinopathy of prematurity (ROP) in premature infants, sickle cell retinopathy, and penetrating ocular trauma.
Exudative (serous) retinal detachment (ERD): Fluid accumulates under the retina without any retinal break and without tractional membranes. The fluid is driven into the subretinal space by disease of the choroid (the vascular layer beneath the retina) or by systemic conditions. The fluid typically shifts position with gravity when the patient’s head changes position—a clinical sign called shifting subretinal fluid. Causes include choroidal tumors (including uveal melanoma and metastatic cancer), malignant hypertension, inflammatory conditions such as Vogt-Koyanagi-Harada syndrome, and central serous chorioretinopathy.
Mixed or combined retinal detachment: Features of two types occur simultaneously, most commonly TRD combined with secondary RRD in advanced proliferative diabetic retinopathy.
ROP-associated tractional detachment (pediatric): In premature infants, incomplete development of retinal blood vessels leads to ischemia and abnormal fibrovascular growth that can tractionally detach the retina. Stage 4A retinopathy of prematurity spares the macula; stage 4B involves it, and stage 5 is a total detachment. This is a leading cause of childhood blindness in premature infants worldwide.

Causes of Retinal Detachment

The specific cause of retinal detachment depends on the type. All three types share the common final result—retinal separation—but through completely different mechanisms.

Causes of Rhegmatogenous Retinal Detachment

The most important initiating event in most RRD cases is posterior vitreous detachment (PVD)—the normal age-related separation of the vitreous gel from the retinal surface. PVD is present in less than 10% of adults under age 50 but in 27% of those aged 60 to 65 and in 63% of those over age 70. As the vitreous separates, it can tear the retina at sites where the vitreous is abnormally adherent. Specific causes include:

Age-related posterior vitreous detachment: the primary trigger. If vitreous traction tears the retina during separation, liquefied vitreous seeps through the tear and progressively lifts the retina away from its support.
Lattice degeneration: a common peripheral retinal thinning condition found in about 7–8% of adults. Areas of lattice are sites of abnormal vitreoretinal adhesion prone to tearing during PVD.
High myopia (nearsightedness): The elongated myopic eye is under greater mechanical stress. About 50% of rhegmatogenous detachment patients are myopic, and persons with more than 3 diopters of myopia have approximately a 10-fold increased risk.
Prior cataract surgery: Retinal detachment occurs in approximately 0.5–0.6% of eyes following modern cataract surgery, and the risk is 15 to 20 times higher when the posterior lens capsule ruptures during the procedure.
Blunt ocular trauma: This can cause retinal dialysis—a separation of the retina at its most anterior edge—as well as direct retinal tears from compressive forces transmitted through the vitreous.
Inherited connective tissue disorders: Stickler syndrome (caused by mutations in the COL2A1, COL11A1, and related collagen genes) is the most common cause of hereditary retinal detachment in childhood. About 24% of Stickler syndrome patients experience retinal tears or detachments at a median age of 14 years. Marfan syndrome and Wagner syndrome also carry elevated retinal detachment risk.

Causes of Tractional & Exudative Detachment

Tractional detachment is caused by fibrovascular membrane formation on the retinal surface, most commonly from proliferative diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy, or penetrating trauma with scarring. The membranes contract and pull the retina inward. Exudative detachment is caused by conditions that disrupt the choroidal blood supply or the RPE’s ability to pump fluid out of the subretinal space—including choroidal tumors, severe high blood pressure, systemic autoimmune disease, and corticosteroid use.

Risk Factors for Retinal Detachment

Retinal detachment affects people of all ages, but risk rises substantially after age 50 and in the presence of specific ocular and systemic conditions. Several key risk factors are modifiable or identifiable before detachment occurs.

Older age: Peak incidence for rhegmatogenous detachment is in the 60 to 70 age group, driven by increasing rates of posterior vitreous detachment. The mean age at diagnosis in the U.S. is approximately 57 years. There is a second peak in younger myopic adults aged 20 to 40.
Male sex: About 57% of U.S. rhegmatogenous retinal detachment cases are in men. A significant healthcare disparity exists: women have a 34% lower odds of receiving timely surgical repair after adjusting for other factors.
Myopia: approximately 10-fold increased risk in persons with more than three diopters of nearsightedness. About half of all phakic RRD patients are myopic.
Prior cataract surgery: Approximately one in five RRD patients in the U.K. had prior cataract surgery. Risk is substantially higher when the posterior capsule ruptures during the procedure.
Family history of retinal detachment: Having had a detachment in one eye confers a 2–10% lifetime risk for the fellow eye. Family history of Stickler syndrome is associated with a hazard ratio of 5.53 for retinal events.
Lattice degeneration: present in 16% of RRD patients in U.S. studies. Most people with lattice degeneration will never have a detachment, but the risk is substantially higher than in the general population.
Symptomatic retinal tears: More than 50% of symptomatic retinal tears with persistent vitreoretinal traction will progress to retinal detachment if left untreated.
Diabetes mellitus: This is the leading systemic cause of tractional detachment through the mechanism of proliferative diabetic retinopathy.
Prematurity: Retinopathy of prematurity develops in premature infants, particularly those born at or before 30 weeks of gestation or weighing 1,500 grams or less. Advanced ROP leads to tractional detachment and is a leading cause of childhood blindness worldwide.
Genetic syndromes: Stickler syndrome, Marfan syndrome, and Wagner syndrome each carry elevated retinal detachment risk and are diagnosed at younger ages than typical RRD.
Trauma: Approximately 10% of rhegmatogenous detachments are trauma-related. Blunt trauma is particularly associated with retinal dialysis.

Screening for & Preventing Retinal Detachment

There is no population-wide screening program for retinal detachment. Screening is targeted to high-risk groups. The most critical message is that certain symptoms require same-day emergency ophthalmological evaluation—these are warning signs that a retinal tear or detachment may be occurring and require evaluation before the situation worsens.

The following symptoms should trigger a same-day call to an ophthalmologist or visit to an emergency eye care facility:

A sudden shower of new floaters—particularly a dramatic increase in number
New flashing lights (photopsia) in the peripheral vision—caused by the vitreous tugging on the retina
A curtain, shadow, or dark veil spreading across any portion of the visual field—this is the detachment itself progressing
Any sudden change in peripheral or central vision in an eye that was previously stable

For high-risk individuals who have not yet developed symptoms, targeted surveillance is recommended. Annual dilated fundus examinations are advised for people with high myopia (more than three diopters), prior retinal detachment in the fellow eye, known lattice degeneration with risk factors, and any inherited connective tissue disorder associated with retinal detachment. Following cataract surgery, periodic dilated examinations help identify retinal changes that occur during the months and years after the procedure. Premature infants meeting ROP screening criteria—gestational age 30 weeks or less, or birth weight 1,500 grams or less—require formal ROP screening beginning at four weeks of chronological age per established protocols.

Prevention strategies include:

Laser photocoagulation (retinopexy) for symptomatic retinal tears: Laser applied around a retinal tear creates a permanent seal (chorioretinal adhesion) within two to three days, reducing the risk of progression from a symptomatic tear to a full detachment from more than 50% to near zero. This is the single most effective preventative intervention available.
Cryotherapy (cryoretinopexy): This is an alternative to laser for tears in locations that laser cannot reach, or when media opacity blocks laser delivery.
Prophylactic treatment in Stickler syndrome: For high-risk patients with genetically confirmed Stickler syndrome, prophylactic laser retinopexy applied to at-risk retinal areas has been shown to substantially reduce the rate of retinal detachment.
Tight glycemic and blood pressure control: This reduces the progression of diabetic and hypertensive retinopathy, lowering the risk of tractional and exudative detachment.
Protective eyewear: In high-risk occupational or athletic environments, proper eye protection significantly reduces the rate of trauma-related retinal detachment.
Genetic counseling for inherited forms: Stickler, Marfan, and Wagner syndromes cannot be prevented, but genetic testing and counseling help affected families understand surveillance needs and allow prophylactic treatment before detachment occurs.

Signs & Symptoms of Retinal Detachment

The hallmark presentation of rhegmatogenous retinal detachment is the sudden onset of painless vision loss or visual field disturbance, typically preceded by new photopsia (flashing lights) and floaters. Retinal detachment is painless—there are no pain fibers in the retina—which is why its symptoms are easily dismissed, delaying care and worsening outcomes. Because the detachment is typically progressive, early symptoms often appear before significant central vision is lost, making prompt evaluation of warning signs critical.

Primary warning symptoms that require same-day evaluation:

Photopsia (flashing lights): brief flickers or flashes of light in the peripheral vision, caused by the vitreous mechanically pulling on the photoreceptors as it separates from the retinal surface. This is frequently one of the earliest symptoms.
New floaters: a sudden shower of dark specks, cobwebs, or a large ring-shaped floater (the Weiss ring from the vitreous detachment footprint). Floaters from a retinal tear may also include brownish dots (pigment cells released from the RPE, called tobacco dust or Shafer’s sign) that indicate a break has occurred.
A curtain, shadow, or veil in the peripheral or central visual field: representing the advancing detachment. The shadow begins at the periphery and can spread toward the center.
Loss of peripheral visual field: This is a blind area or scotoma corresponding to the detached region.
Blurred vision: This can happen as the detachment extends toward the macula.
Loss of central visual acuity: occurring when the macula detaches. This is the point at which the prognosis changes dramatically.

In tractional detachment from proliferative diabetic retinopathy, the presentation is typically quite different—a slow, insidious, painless progressive visual field loss without acute photopsia or floaters. These detachments are often identified on routine diabetic eye screening before the patient notices any symptoms at all. In exudative detachment, the visual field defect may shift with changes in head position—a characteristic feature reflecting the gravity-dependent mobility of the subretinal fluid.

Prognostic Categories—Macula Status

The single most important prognostic factor is whether the macula (fovea) remains attached at the time of surgery. Macula-on detachment, in which the central vision area is still intact, is treated as a same-day surgical emergency, and 90% of successfully repaired eyes achieve 20/40 vision or better. Macula-off detachment, in which the central retina has detached, carries a far worse prognosis—only about 50% of patients regain 20/50 vision or better, and if the macula has been detached for a week or more, this level of recovery is rarely achieved.

Symptoms by Age Group

In premature infants with ROP: Retinal detachment is entirely asymptomatic and is detected only on mandatory screening examinations. In severe stage 5 total detachment, leukocoria (a white pupillary reflex visible in photographs) may be the presenting sign.
In children with Stickler syndrome or other hereditary conditions: Retinal events typically begin at a median age of 14 years, often in the setting of childhood myopia.
In adults aged 60 to 70: The classic presentation is acute onset of photopsia, new floaters, and a visual field curtain, often developing over hours. In patients with diabetes: tractional detachment is most often diagnosed on routine screening without acute symptoms.

Diagnosing Retinal Detachment

Retinal detachment is typically diagnosed during urgent ophthalmological evaluation triggered by acute visual symptoms. The diagnosis is primarily clinical—made by a retinal specialist examining the eye directly—but imaging confirms and characterizes the detachment for surgical planning. The most important initial determination is whether the macula has detached, which sets the surgical urgency and the expected visual prognosis.

Indirect ophthalmoscopy with scleral indentation: the gold-standard diagnostic examination. The pupils are dilated, and the doctor examines the entire retina using a wide-angle lens and bright light source while gently pressing on the outer eye wall (scleral depression) to bring the extreme peripheral retina into view. This technique identifies retinal breaks, tears, dialyses, lattice degeneration, and the full extent of the detachment. It also allows detection of Shafer’s sign—pigment cells in the vitreous cavity that are a highly sensitive indicator of a retinal break.
Slit-lamp biomicroscopy: examines the vitreous and anterior structures of the eye in magnified detail. Tobacco dust (Shafer’s sign) in the anterior vitreous, vitreous hemorrhage, and epiretinal membranes are identified. The degree of proliferative vitreoretinopathy (PVR)—scarring that complicates surgery—is assessed.
B-scan ultrasonography (ocular ultrasound): used when direct visualization of the retina is blocked by dense vitreous hemorrhage, cataract, or corneal clouding. The detached retina appears as an echogenic (bright) membrane on the ultrasound image. This test is also increasingly used in emergency settings. It can distinguish retinal detachment from other causes of a dark curtain or visual loss.
Optical coherence tomography (OCT): provides high-resolution cross-sectional images of the retinal layers. It confirms the presence and extent of subretinal fluid, determines precisely whether the fovea is still attached (macula-on vs. macula-off status), and assesses the integrity of the photoreceptor layer—a critical factor in predicting visual recovery after surgery. OCT is also essential for monitoring the retina in the weeks and months after surgical repair.
Wide-field fundus photography: captures detailed photographic documentation of the peripheral retina, retinal breaks, and the extent of detachment. Essential for the medical record and for comparing the retinal status at serial examinations over time.
Fluorescein angiography: This is used specifically in the evaluation of exudative detachment, to map leakage from tumors, inflammatory lesions, or abnormal choroidal blood vessels that are generating the subretinal fluid.
Computed tomography (CT) or magnetic resonance imaging (MRI) scan: These are used when trauma has occurred (to detect intraocular foreign bodies or orbital injury), when a choroidal tumor is suspected as the cause of exudative detachment, or when other imaging is insufficient.

Treating Retinal Detachment

Retinal detachment is a surgical condition. No eye drop or oral medication can reattach the retina. The goal of treatment is anatomical re-attachment of the retina and preservation or recovery of visual function. Overall, approximately 95% of patients achieve anatomical success, and 70–90% are reattached in a single operation. For exudative detachment, treatment is directed at the underlying systemic or ocular cause. For tractional and rhegmatogenous detachment, surgery is the definitive intervention, and the choice of technique depends on the type, location, and number of retinal breaks, the degree of associated scarring, the patient’s age, and whether the natural lens is still present.

Pneumatic Retinopexy

Pneumatic retinopexy is the least invasive surgical option, performed as an office procedure without entering the operating room. The surgeon injects an expansile gas bubble (sulfur hexafluoride or perfluoropropane) into the vitreous cavity, then applies laser or cryotherapy to seal the retinal break. The patient maintains a specific head position—sustained for one to several days—so the gas bubble floats against the break and holds the retina flat while the laser-created adhesion heals. It is most appropriate for superior, single, or small breaks in suitable patients. The PIVOT randomized controlled trial found that patients treated with pneumatic retinopexy reported better vision-related quality of life and mental health scores at six months compared to those treated with vitrectomy, reflecting its lower operative burden. Limitations include the need for sustained postoperative positioning and a higher rate of reoperation in complex cases. Patients with gas in the eye cannot fly or undergo general anesthesia with nitrous oxide until the bubble has fully absorbed.

Scleral Buckling

Scleral buckling is a procedure in which a silicone element—either a segmental pad placed over the break site or a 360-degree encircling band—is sutured to the outside of the eye wall. The buckle indents the sclera inward, bringing the eye wall closer to the detached retina, relieving vitreoretinal traction, and allowing the break to close. Cryotherapy or laser seals the break. Scleral buckling does not require entry into the eye (there is no intraocular component), which carries a lower risk of infection and avoids acceleration of cataract in the natural lens. It is particularly favored for younger phakic (natural lens intact) patients, trauma-associated dialysis, inferior retinal breaks, and pediatric retinal detachment, including Stickler syndrome cases. Possible complications include temporary double vision, induced myopia from the indentation, and buckle-related complications.

Pars Plana Vitrectomy

Pars plana vitrectomy (PPV) is the most widely used and versatile technique, and its use has increased steadily in U.S. practice. The surgeon inserts fine cutting and aspirating instruments through tiny self-sealing incisions in the sclera, removes the vitreous gel from inside the eye, directly relieves vitreoretinal traction, and applies laser endophotocoagulation to seal the retinal breaks. A tamponade agent is then injected to hold the retina flat while healing occurs. Short-acting gas (sulfur hexafluoride, absorbed in two to three weeks) is used for most straightforward detachments. Long-acting gas (perfluoropropane, absorbed in six to eight weeks) is preferred for inferior or complex breaks. Silicone oil—a permanent tamponade that requires a second surgery for removal—is used for detachments complicated by severe proliferative vitreoretinopathy (PVR), a form of retinal scarring that is the main cause of surgical failure. PPV is indicated for pseudophakic (no natural lens) and aphakic (no lens at all) patients, those with vitreous hemorrhage or giant retinal tears, complex or recurrent detachments, posterior breaks, diabetic tractional detachment, and any detachment with significant PVR. Because PPV reliably accelerates cataract formation in the natural lens, many surgeons combine cataract removal with vitrectomy in the same surgical session for phakic patients.

Drug Treatments

For tractional detachment from proliferative diabetic retinopathy and retinopathy of prematurity, intravitreal anti-vascular endothelial growth factor (VEGF) injections are an important adjunct. VEGF is the protein that drives abnormal blood vessel growth in both conditions. Anti-VEGF agents—including bevacizumab (Avastin®), ranibizumab (Lucentis®), and aflibercept (Eylea®)—are injected into the vitreous to shrink neovascular membranes before surgery (reducing intraoperative bleeding in diabetic tractional detachment) or as primary treatment in certain stages of retinopathy of prematurity. For exudative detachment, treatment targets the underlying cause: systemic corticosteroids for Vogt-Koyanagi-Harada syndrome, aggressive antihypertensive therapy for hypertensive retinopathy, and photodynamic therapy (PDT) with verteporfin for central serous chorioretinopathy. For patients with advanced proliferative vitreoretinopathy, adjunctive anti-proliferative agents have been investigated but none are currently standard of care.

Living with Retinal Detachment

The prognosis for retinal detachment depends on the type, how quickly treatment was received, and most critically—whether the macula was still attached at the time of surgery. Patients with macula-on detachment who receive prompt treatment have an excellent chance of recovering functional vision, with 90% achieving 20/40 or better after successful repair. For patients with macula-off detachment, about 50% recover useful central vision, and prolonged detachment before surgery significantly reduces this chance. After surgery, vision continues to improve for months as the retina recovers, and rehabilitation services, including low-vision aids and electronic vision enhancement devices, are available for patients with permanent visual loss. All patients who have had a retinal detachment should be followed carefully and must keep the fellow eye under regular surveillance—the risk of detachment in the second eye is 2–10%. Any new photopsia, floaters, or visual field change in either eye should be evaluated the same day without waiting. Gas tamponade after vitrectomy or pneumatic retinopexy means no air travel and no nitrous oxide anesthesia until the gas is fully absorbed—your surgeon will tell you when this restriction has been lifted. With advances in vitreoretinal surgery, even complex and recurrent detachments can now be successfully repaired in the large majority of patients.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of retinal detachment and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.

Take the Ophthalmology & Visual Sciences Residency Programs Virtual Tour